Tower Research Capital LLC (Trc) Gain Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,842 shares of GANX stock, worth $7,553. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,842
Previous 1,729
180.05%
Holding current value
$7,553
Previous $2,000
300.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding GANX
# of Institutions
23Shares Held
2.39MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$917,9190.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$883,1620.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$521,9630.01% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$424,2760.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA145KShares$226,5380.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $18.5M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...